GovChime
Notice ID: cea9a86e04cc4d0b9d33a7a80c408696Combined Synopsis/SolicitationArchived

RNA Sequencing Service

Archived on October 7, 2025. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM CDT
Posted
September 17, 2025
Notice type
Combined Synopsis/Solicitation
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Agriculture

Notice details

Last updated
Nov 8, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
1232SA25Q0855
Notice ID
cea9a86e04cc4d0b9d33a7a80c408696

Description

Amendment 0002 Posted. Amendment 0001 Posted. This is a combined synopsis/solicitation for commercial item prepared in accordance with the format in FAR subpart 12.6 and FAR Part 13, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested. The solicitation number is 12805B24Q0216 and is issued as a request for quotation (RFQ). This solicitation document incorporates those provisions and clauses in effect through Federal Acquisition Circular 2025-05 with supplemental USDA Overhauled FAR Deviations included. The associated NAICS Code is 541714 and the Small Business Size Standard is 1,000 Employees. This is an total small business set aside. The USDA, Agricultural Research Service, Fargo, ND has a requirement for RNA sequencing. The Government intends to award a firm fixed price purchase order. The requirements are further detail in the attached Requirements Document. The DELIVERY ADDRESS is: PA CEREAL CROPS RESEARCH 1616 ALBRECHT BLVD NORTH FARGO ND 58102 DOCUMENTS TO BE INCLUDED IN QUOTE: In order to be considered for award, Offerors shall respond by: 1) Addressing all of the requirements of the RFQ submission documents, and be valid for at least 60 days after receipt of quote. 2) Have an Active SAM.gov registration; the Representation and Certification section should also be completed electronically in the System for Award Management (SAM) at www.sam.gov. Any amendment and documents related to this procurement will be available electronically at the Government Point of Entry (sam.gov). FAR clauses 52.212-1, 52.212-2, 52.212-3, 52.212-4 and 52.212-5 (and any addenda to those clauses) are included in the attached clauses and provisions document. Additionally, other contract requirements and terms/conditions can be located in the same document. The Government anticipates award of a contract resulting from this solicitation to the responsible offeror whose quote conforms to the specifications that will be the most advantageous to the Government in accordance with FAR 13.106-2 considering three major areas: technical acceptance, past performance and price. Quotes will be evaluated by performing a comparative evaluation in accordance with FAR 13.106-2(b)(3) to determine which quote meets the lowest price technically acceptable evaluation methodology. All sources wishing to quote shall furnish a quotation by 10:00 a.m. Central Time, on or before September 11, 2025. Quotations are to be sent via email to Kelly Wright at kelly.wright@usda.gov. Failure to provide the required information in the requested format may result in quotes not being considered for award. Attached Provisions/Clauses apply to this RFQ and any subsequent award.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

Files (8)

  • Solicitation 1232SA25Q0855-0002.pdf

    1.0 MBAdded in Combined Synopsis/Solicitation version 5Posted
    Download
  • Solicitation_1232SA25Q0855_Amd_0002.pdf

    88 KBAdded in Combined Synopsis/Solicitation version 5Posted
    Download
  • Attachment 1 Rev 2 - RNA-Seq Performance Work Statement.doc

    82 KBAdded in Combined Synopsis/Solicitation version 5Posted
    Download
  • Attachment 1 Rev 1 - RNA-Seq Performance Work Statement.doc

    82 KBAdded in Combined Synopsis/Solicitation version 2Posted
    Download
  • 1232SA25Q0855 Amendment 0001.pdf

    125 KBAdded in Combined Synopsis/Solicitation version 2Posted
    Download
  • Solicitation_1232SA25Q0855.pdf

    842 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • Attachment 1 - RNA-Seq Performance Work Statement.doc

    81 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • Attachment 2 - Wage Determination 2015-4969 Rev 29.pdf

    45 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download

Lifecycle

  1. 1
    Version 1Combined Synopsis/SolicitationArchived

    RNA Sequencing Service

    Notice 5fda82685fc645a2940364f9987e5e29 on SAM.gov

  2. 2
    Version 2Combined Synopsis/SolicitationArchived

    RNA Sequencing Service

    Notice c12f6bc842a04ac0900f1041bb1fe9c1 on SAM.gov

  3. 5
    Version 5Combined Synopsis/SolicitationArchivedCurrent

    RNA Sequencing Service

    Notice cea9a86e04cc4d0b9d33a7a80c408696 on SAM.gov

  4. 7
    Version 7Award NoticeArchived

    Type changed from Combined Synopsis/Solicitation to Award Notice

    RNA Sequencing Service

    Notice 9363ceaedc8c473a8693042ad53b992f on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Amendment 0001 to this notice is to push out the anticipated posting of the solicitation to late November 2026. This is a pre-solicitation notice to synopsize the intention of the Defense Health Agency Contracting Activity (DHACA) to issue a Request for Proposal (RFP) for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle covering military medical research and development services. A historical pre-solicitation notice was posted under Notice ID# HT942626RE002, although there were various delays with getting a solicitation out in Fiscal Year 2026. This notice is taking over where Notice ID# HT942626RE002 left off. No further delays are anticipated at this time for this on-ramp. The eventual RFP will be set-aside for small businesses certified under the Small Business Administration 8(a) Program. The Government anticipates making multiple new awards under this on-ramp, and all new awards will align with the existing unrestricted contract vehicle. This notice is not a request for proposals and does not commit the Government to any contractual agreement. The OMNIBUS IV contract vehicle was awarded under full and open competition with a base ordering period of 20 June 2022 through 19 June 2027 and an Option Ordering Period of 20 June 2027 - 19 June 2032. Task orders may be competed under fair opportunity (providing all Contract Holders within a Market Segment the opportunity to submit a proposal) or an exception to fair opportunity (such as set-asides for small businesses or applicable small business socioeconomic categories). The cumulative ceiling of this unrestricted IDIQ contract vehicle is $10 billion. To date, the accumulated awarded task order value (including future unexercised option periods) is over $690 million across 61 task orders. Task Orders have been issued by a growing number of end users including DHACA, the U.S. Army Medical Research Acquisition Activity (now integrated into DHACA), the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. When excluding the task orders simply providing a minimum guarantee to the existing Contract Holders, 61 task orders have been issued off this contract vehicle with 8 task orders being set aside for the 8(a) Program and 15 task orders being awarded to an 8(a) Participant (based on the most recent representations at the contract level). 42 task orders have been awarded so far to small businesses under this contract vehicle. Of the 61 task orders, 95% were awarded during the Government Fiscal Years 2024 - 2026. Please see attachments for further details.
-Pre-SolicitationOpen
Please see attached Sources Sought. Questions & Answers attached.
-Market Research11/12/2026
Amendment 001 - 10/30/26 - Updated the proposal due date from 2/1/27 at 5:00 pm to 1/22/27 at 5:00 pm. Updated the Special Notice Archive date from 15 days after response date to 09/30/27. In accordance with FAR 6.102(d)(2) and 35.016, the US Food and Drug Administration (FDA) solicits for the acquisition of basic and applied research and development proposals to support regulatory science and innovation through this Broad Agency Announcement (BAA). Research and development activities acquired under this BAA are intended to advance scientific knowledge in specific research areas as well as sub areas of interest defined within the BAA that serve the FDA in accomplishing its mission to protect and promote the health of our nation. Proposals submitted under this announcement are not limited solely to the PSC code "AJ11" specified in this announcement. FDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation.
-Special Notice01/22/2027
The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform the fiscal year 2027 (FY27) Alzheimer’s Research Program (AZRP) research focus areas and associated research funding opportunities. Although FY27 federal funds have not yet been appropriated, the AZRP is collecting this information solely to support strategic program planning. This inquiry does not commit the program to incorporating this feedback into FY27 or any future AZRP funding opportunities. The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public. This RFI should not be construed as a solicitation or an obligation on the part of the AZRP or the Department of War (DoW). BACKGROUND: The CDMRP represents a unique partnership between the U.S. Congress, the military, and the public to fund innovative and impactful medical research in targeted program areas. The CDMRP AZRP’s vision is to mitigate the impact of Alzheimer's and related dementias associated with TBI, military, and diverse risks. The AZRP’s mission is to fund impactful, solution-oriented research to address critical needs and improve quality of life for Service Members, Veterans, their Families, and the public who are living with Alzheimer's disease and related dementias. Appropriations for the AZRP from FY11-26 totaled $228 million. As of October 2026, FY27 funds for the AZRP have not been appropriated. If appropriated, the CDMRP will utilize its two-tier review process https://cdmrp.health.mil/about/2tierRevProcess) to efficiently manage the AZRP. Additional information about the AZRP can be found here: https://cdmrp.health.mil/azrp/ RESPONSE INSTRUCTIONS: Please provide responses to this RFI by clicking on the following link: https://www.surveymonkey.com/r/FY27-AZRP-RFI
-Market Research12/04/2026
The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform the fiscal year 2027 (FY27) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) research focus areas and associated research funding opportunities. Although FY27 federal funds have not yet been appropriated, TBIPRP is collecting this information solely to support strategic program planning. This inquiry does not commit the program to incorporating this feedback into FY27 or any future TBIPHRP funding opportunities. The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public. This RFI should not be construed as a solicitation or an obligation on the part of the TBIPHRP or the Department of War (DoW). BACKGROUND: The CDMRP represents a unique partnership between the U.S. Congress, the military, and the public to fund innovative and impactful medical research in targeted program areas. The CDMRP TBIPHRP’s vision is to optimize the prevention, assessment, and treatment of psychological health conditions and/or traumatic brain injuries. The TBIPHRP’s mission is to fund research to understand, prevent and treat psychological health conditions and/or traumatic brain injuries that accelerates solutions to improve the health and healthcare of Service Members, their Families, Veterans, and the American public. Appropriations for the TBIPHRP from FY21-24 and FY26 totaled $740.5 million. As of October 2026, FY27 funds for the TBIPHRP have not been appropriated. If appropriated, the CDMRP will utilize its two-tier review process https://cdmrp.health.mil/about/2tierRevProcess) to efficiently manage the TBIPHRP. Additional information about the TBIPHRP can be found here: https://cdmrp.health.mil/tbiphrp/ RESPONSE INSTRUCTIONS: Please provide responses to this RFI by clicking on the following link: https://www.surveymonkey.com/r/FY27-TBIPHRP-RFI
-Market Research12/11/2026

Additional Details

Solicitation Number

1232SA25Q0855

Archive Date

Oct 7, 2025